Crinetics Pharmaceuticals (CRNX) to Announce Quarterly Earnings on Tuesday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is expected to be posting its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Crinetics Pharmaceuticals to post earnings of ($1.23) per share and revenue of $14.8420 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its earnings results on Thursday, May 7th. The company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million during the quarter, compared to the consensus estimate of $8.51 million. During the same period in the prior year, the business posted ($1.04) earnings per share. Crinetics Pharmaceuticals’s revenue for the quarter was up 2873.4% compared to the same quarter last year. On average, analysts expect Crinetics Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Stock Up 0.1%

NASDAQ:CRNX traded up $0.12 during mid-day trading on Tuesday, hitting $83.97. 394,315 shares of the company traded hands, compared to its average volume of 2,291,273. The stock’s fifty day moving average price is $50.36 and its 200-day moving average price is $45.34. Crinetics Pharmaceuticals has a one year low of $25.83 and a one year high of $84.00. The firm has a market cap of $8.85 billion, a price-to-earnings ratio of -16.37 and a beta of 0.23.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Citizens Jmp downgraded shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Lifesci Capital cut shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen raised Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Cantor Fitzgerald cut Crinetics Pharmaceuticals from an “overweight” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $81.00.

Insider Buying and Selling

In other Crinetics Pharmaceuticals news, Director Coelho Rogerio Vivaldi sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the transaction, the director directly owned 19,225 shares of the company’s stock, valued at $769,000. The trade was a 13.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 6,900 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the sale, the director directly owned 6,400 shares in the company, valued at approximately $228,288. This represents a 51.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of Crinetics Pharmaceuticals by 44.3% in the third quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company’s stock worth $349,110,000 after acquiring an additional 2,574,683 shares during the period. Farallon Capital Management LLC increased its stake in shares of Crinetics Pharmaceuticals by 20.2% in the 4th quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company’s stock valued at $322,736,000 after purchasing an additional 1,163,000 shares in the last quarter. Janus Henderson Group PLC boosted its position in Crinetics Pharmaceuticals by 15.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,440,691 shares of the company’s stock worth $206,604,000 after purchasing an additional 581,900 shares in the last quarter. RTW Investments LP grew its holdings in Crinetics Pharmaceuticals by 54.9% in the fourth quarter. RTW Investments LP now owns 1,351,326 shares of the company’s stock valued at $62,904,000 after purchasing an additional 478,939 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of Crinetics Pharmaceuticals by 157.7% in the third quarter. Ameriprise Financial Inc. now owns 614,816 shares of the company’s stock valued at $25,607,000 after buying an additional 376,206 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.